Tim McCarthy, chairman of (),says lupus treatment Lupuzor will be entered into managed access programme to allow sufferers whose doctors recommend it.
Immupharma will get 'real-world' data from the MAP with up to 500 patients to receive the drug free of charge for two years.
That is more than twice the number of patients studied in all clinical trials for Lupuzor to date.
One big advantage is that' real-world' data can be used to supplement a regulatory filing.
Merck's Keytruda I/O cancer treatment made use MAP extensively for example.
An extension study to Lupozor's phase III study will also report next year, said McCarthy.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE